ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 855

Seasonality in ANCA-Associated Vasculitis

Luciano Enrique Pompermayer1, Marina Scolnik1, Valeria Scaglioni2, Maria de los Angeles Gallardo1 and Enrique R. Soriano3, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology, Hospital Italiano, Buenos Aires, Argentina, 3Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  pathogenesis of ANCA-associated vasculitis (AAV) is multifactorial and most likely involves the interaction of environmental and genetic factors. Environmental seasonal exposures may play a role in the manifestation of the disease and incidence of relapses. Our objective was to investigate whether there are different clinical manifestations according to the seasonal period of the beginning of symptoms and if frequency of relapses differs in seasons in patients with ANCA vasculitis.  

Methods: Patients with diagnosis of ANCA vasculitis (Chapel Hill 2012) (Granulomatosis with polyangiitis [GPA], Eosinophilic granulomatosis with polyangiitis [EGPA], Microscopic polyangiitis [MPA], and renal limited ANCA vasculitis [RLV]) seen between years 2000 and 2014 were included. Medical records we reviewed and dates of beginning of symptoms (symptoms included in the Birmingham vasculitis activity score attributed to the disease) and dates of relapses (recurrence of symptoms or new symptom attributed to vasculitis) were identified. Clinical and serological manifestations of ANCA vasculitis in patients beginning their disease in autumn-winter were compared with those beginning in spring-summer. Rate of relapses in the different seasonal periods was also compared. 

Results: one hundred patients with AAV were included (females 70%, CI 60.9-79.1; mean age at diagnosis 58.4, SD 18.8, GPA=38, MPA=19 EGPA=15, RLV, =28). Forty seven patients began their vasculitis symptoms in autumn-winter, and another 47 in spring-summer. Dates of initial symptoms could not be established in 6 patients. Patients’ characteristics at disease onset are compared in table 1. Clinical manifestations were similar in patients beginning their disease in different seasons except for sinus involvement that was more frequent in those starting symptoms in autumn-winter. A total of 26 patients (26%, GPA= 11, EGPA=7, MPA=4 and RLV=4) had relapses of AAV during follow-up, with a total of 30 relapses. Relapses were more frequent in autumn-winter (n=21) than in spring-summer (n=9) (p=0.004) for all patients, and in particular in GPA (p=0.03) and EGPA (p=0.03) (table 2).

Conclusion: no disease characteristic pattern at disease onset was observed according to seasonal period of the beginning of AAV. Relapses were more frequent in autumn-winter in GPA and EGPA, suggesting that environmental seasonal exposures may trigger them.

Table 1. ANCA vasculitis patients grouped by season of beginning of symptoms

 

Beginning of symptoms in autumn-winter

(n=47)

Beginning of symptoms in spring-summer

(n=47)

P

Females, % (CI95)

74.5 (61.7-87.2)

63.8 (49.8-77.9)

0.264

Age at diagnosis, media (SD)

58.9 (SD 19.2)

59.1 (18.2)

0.98

Follow up, years, median (IQR)

6.9 (2.5-9.7)

6 (1.7-9.4)

0.54

GPA, n (%)

18 (38.3)

16 (34)

0.67

EGPA, n (%)

8 (17)

6 (12.7)

0.44

MPA, n (%)

8 (17)

11 (23.4)

0.56

LRV, n (%)

13 (27.7)

14 (29.8)

0.82

ANCA C positive, % (CI)

34.8 (20.7-48.9)

34.1 (19.7-48.5)

0.94

ANCA P positive, % (CI)

47.9 (35.2-62.8)

52.1 9 (0.7-70.4)

0.6

Initial clinical manifestations, % (CI)

–        Renal

–        Pulmonar infiltrates

–        Alveolar Hemorrhage

–        Fever

–        Constitutional

–        Ocular

–        Sinus

–        Hearing loss

–        Neuropathy

–        Cutaneous

66 (52-79.8)

27.7 (14.6-40.8)

10.6 (1.6-19.7)

21.3 (9.3-33.3)

31.9 (18.3-45.6)

4,3 (1.7-10.2)

40.4 (26.1-54.8)

10.6 (1.6-19.7)

12.8 (3-22.5)

8.5 (0.3-16.7)

68.1 (54.4-81.7)

27.7 (14.6-40.8)

8.5 (0.3-16.7)

23.4 (11-35.8)

36.2 (22.1-50.2)

4,3 (1.7-10.2)

21.3 (9.3-33.3)

14.9 (4.5-25.3)

14.9 (4.5-25.3)

14.9 (4.5-25.3)

0.83

1

0.73

0.8

0.66

1

0.04

0.54

0.77

0.34

Relapses during follow up, % (CI)

31.9 (18.3-45.6)

21.3 (9.3-33.3)

0.243

Table 2. Relapses of ANCA vasculitis grouped by season 

 

Relapses in autumm-winter

(n=21)

Relapses in spring-summer

(n=9)

P

Total of ANCA vasculitis relapses, n

21

9

0.004

GPA, n

11

4

0.03

EGPA, n

6

1

0.03

MPA, n

3

1

0.5

LRV, n

1

3

0.5


Disclosure: L. E. Pompermayer, None; M. Scolnik, None; V. Scaglioni, None; M. D. L. A. Gallardo, None; E. R. Soriano, Abbvie; Janssen; UCB; Roche; Bristol Myers Squibb, 2,Abbvie; UCB; Janssen; Roche; Bristol Myers Squibb; Pfizer; Novartis, 8.

To cite this abstract in AMA style:

Pompermayer LE, Scolnik M, Scaglioni V, Gallardo MDLA, Soriano ER. Seasonality in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/seasonality-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/seasonality-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology